With the hope that disease-modifying treatments could target the molecular basis of
Parkinson's disease, even before the onset of symptoms, we propose a biologically based …

Parkinson's disease (PD) is clinically, pathologically, and genetically heterogeneous,
resisting distillation to a single, cohesive disorder. Instead, each affected individual develops …

Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical
presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; …

The genetic landscape of Parkinson's disease (PD) is characterised by rare high penetrance
pathogenic variants causing familial disease, genetic risk factor variants driving PD risk in a …

One of the most common monogenic forms of Parkinson disease (PD) is caused by
mutations in the LRRK2 gene that encodes leucine-rich repeat kinase 2 (LRRK2). LRRK2 …

Following Alzheimer's, Parkinson's disease (PD) is the second-most common
neurodegenerative disorder, sharing an unclear pathophysiology, a multifactorial profile …

Background: Open Access Editor's Choice Review Monogenic Parkinson's Disease:
Genotype, Phenotype, Pathophysiology, and Genetic Testing by Fangzhi Jia 1, 2, Avi Fellner …

Cell-replacement therapies have long been an attractive prospect for treating Parkinson
disease. However, the outcomes of fetal tissue-derived cell transplants in individuals with …

Mitochondrial dysfunction represents a well-established player in the pathogenesis of both
monogenic and idiopathic Parkinson's disease (PD). Initially originating from the observation …

Background Parkinson's disease is a progressive neurodegenerative disorder with
multifactorial causes, among which genetic risk factors play a part. The RAB GTPases are …